Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635 | ISIN: INE0DK501011 | Industry: Pharmaceuticals
| Falling Comet

190.6500 -6.38 (-3.24%)

NSE Aug 01, 2025 15:31 PM

38.08% Fall from 52W High

Volume: 5.0M

Piramal Pharma Ltd.

25 Sep 2024

190.65

-3.24%

Geared to drive robust operating leverage across segments

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment.

Motilal Oswal decreased Buy price target of Piramal Pharma Ltd. to 240.0 on 29 Jul, 2025.